Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Piramal announces launch of Cinacalcet by its partner, Slate Run Pharmaceuticals, in the U.S.

Posted On: 2019-03-12 14:27:29

Piramal Enterprises Limited ('PEL', 'Piramal', NSE: PEL, BSE: 500302) announced that one of its partners for its global pharma businesses - Slate Run Pharmaceuticals LLC. ('Slate Run'), has launched generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the United States.

Piramal's subsidiary, Piramal Healthcare (UK) Limited ('PHL'), has partnered with Slate Run Pharmaceuticals with the goal of developing a non-infringing formulation of cinacalcet hydrochloride tablets. Cinacalcet tablets are indicated for the treatment of secondary hyperthyroidism ('HPT') in adult chronic kidney disease patients on dialysis and hypercalcemia in adult patients with parathyroid carcinoma.

"As part of our patient focus strategy, we are working with global pharmaceutical firms, to co-develop products, where our R&D competencies can bring about a differentiated and cost effective value proposition for the global healthcare system. With world class R&D and fully integrated network of manufacturing capabilities across the globe, for both drug substance and drug product, Piramal is uniquely positioned to solve both complex chemistries and formulation challenges in the pharmaceutical domain with innovative solutions for partners." said Vivek Sharma, CEO - Piramal Pharma Solutions, Piramal Group.

PHL received the final Abbreviated New Drug Application ('ANDA') approval for its generic abbreviated bio-equivalent ('AB') rated version of Amgen Inc.'s Sensipar® (cinacalcet hydrochloride) tablets on August 1, 2018. Piramal received a favourable US district court ruling which holds that Piramal's generic version does not infringe any of the asserted claims of Amgen's Patent No. 9,375,405. Amgen has filed an appeal which is currently pending in the U.S. Court of Appeals for the Federal Circuit.

Piramal will continue to focus on assisting its partners with a culture that is built around the pillars of Customer Centricity, Quality, and Innovation.

Shares of PIRAMAL ENTERPRISES LTD. was last trading in BSE at Rs.2661.15 as compared to the previous close of Rs. 2585.95. The total number of shares traded during the day was 43262 in over 2078 trades.

The stock hit an intraday high of Rs. 2675.05 and intraday low of 2586. The net turnover during the day was Rs. 114817611.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

James Warren Tea Ltd board approves buy back at Rs. 115

Escorts Ltd appoints Mr. Shailendra Agrawal as an Executive Director

EID Parry Ltd to invest Rs. 70 crore in subsidiary

Infosys to enter into agreement with The House Fund II, L P

US FDA completes audit of R&D facility of Aurigene Discovery Technologies Ltd

Jindal Stainless Park Ltd becomes subsidiary of Jindal Stainless Ltd

Raghav Productivity Enhancers bestowed with 'SME - Empowering India Awards 2019'

Tejas Networks appoints two new board of directors

Kallam Textiles Ltd calls for rights issue committee meeting on March 27, 2019

Tata Steel Bsl Ltd allots OCRPS worth Rs. 6700 crore to Tata Steel

Galaxy Surfactants Ltd board to consider interim dividend on March 29, 2019

ICRA reaffirms rating of Deepak Nitrite Ltd

Bharat Gears Ltd board fixes April 3, 2019 as record date for rights issue

Amber Enterprises India Ltd to acquires 80% in Sidwal Refigeration Industries Pvt Ltd

Sukhjit Starch & Chemicals Ltd board to consider allotment of bonus shares on March 30, 2019

EID Parry Ltd declares second interim dividend of Rs. 1

Alkem Laboratories Ltd update on US FDA Inspection at its facility located at St. Louis, USA

Mac Hotels Ltd calls for board meeting on March 29, 2019

Cadila's Pharmaceutical Technology Centre successfully completes USFDA inspection

Zydus receives final approval from the USFDA for Lurasidone Hydrochloride Tablets

Aurionpro wins prestigious order from a leading bank in Singapore

Steelco Gujarat Ltd updates on loan agreement with Costronal Holdings SA

Caplin Steriles gets USFDA approval for Glycopyrrolate Injection

Lupin launches generic Levothyroxine Sodium Tablets USP

Barclays and TCS partner to Help Children with Locomotor Disabilities

Mahindra World City, Jaipur launches eco-friendly bicycle sharing services

GVK Group stake in Mumbai Airport to increase to 74%

Tata Power SED bags Rs 1,200 crore contract from the Ministry of Defence

Woodsvilla Ltd fixes record date for sub-division of equity shares

Alembic Pharma receives USFDA Approval for Azelastine Hydrochloride Ophthalmic Solution, 0.05%

PVR Cinemas launches its 10th multiplex in Telangana

Garden Reach Shipbuilders & Engineers Ltd board to consider interim dividend on March 24, 2019

Jubilant Life Sciences Ltd updates on USFDA inspection at API facility, Nanjangud

MeDirect Bank Belgium, the Online Only Bank, Extends its Product Offerings with Infosys Finacle

Hansard Global Plc Selects SaaS-Based Majesco LifePlus Solutions to Transform their Business

ENIL commences radio station at Asansol

Mac Charles India Ltd seeks shareholders approval for related party transactions

1st Foundation Day of ICT-IOC

Infosys Ltd board to consider Q4, FY19 results on April 11 - 12, 2019

Syngene International wins CMO Leadership Awards presented by Life Science Leader Magazine

Rane Madras Ltd to invest $20 mn in US arm

Government to divest 15% of KIOCL Ltd through FPO

Manappuram Finance Ltd to acquire 100% in Manappuram Comptech & Consultants Ltd

BEML Ltd board declares interim dividend of Rs. 4.50

Power supply restored at Amit Spinning Industries Ltd's factory

Pierer Industrie and Bajaj in discussions for Bajaj to participate at KTM Industries level

PFC signs agreement to acquire majority stake in REC Limited

Infosys and Roland-Garros Partner for Digital Innovation

DIAL awards the Commercial Development Rights at Aerocity, Delhi to a consortium led by M/s Bharti Realty

Bosch Ltd to form JV with Prettl India Pvt Ltd







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019